🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Manchester
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Manchester

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2852 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
2852
Studies in scope
industry-sponsored, all four open statuses
1378
Recruiting now
open to new participants
540
Lead sponsors
across recruiting studies
Top sites
London 73 Manchester 28 Sutton 25 Birmingham 17 Cambridge 15
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca74 Merck Sharp & Dohme LLC39 Janssen Research & Development, LLC28 Hoffmann-La Roche25 AbbVie17 Clear sponsor filter
Site city
London73 Manchester28 Sutton25 Birmingham17 Cambridge15
All 92 cities
Target enrolment
to
28 of 2852 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
NCT07572006Hematologic Neoplasms
Janssen Research & Development, LLC
Phase 1
360
Manchester
2026-05-13
Recruiting
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
NCT07319871Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 1
40
Manchester, Sutton
2026-01-14
Recruiting
A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting
NCT07230691Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Observational
380
Bath, Cardiff, Eastbourne, Guildford, Heath Town, London, Manchester, Sutton
2025-12-03
Recruiting
A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia
NCT07295951Acute Lymphoblastic Leukemia, Acute Leukemias, Acute Myeloid Leukemia
Janssen Research & Development, LLC
Phase 1
10
Manchester
2025-11-18
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 3
1,203
Birmingham, London, Manchester, Sutton
2025-09-02
Recruiting
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
NCT07082920Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 1
140
Manchester, Sutton
2025-07-07
Active, closed
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT06618001Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms
Janssen Research & Development, LLC
Phase 1
64
Cambridge, London, Manchester
2025-01-14
Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT06667076Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 2
480
Greater London, Liverpool, London, Manchester, Sutton, Torquay
2024-12-16
Recruiting
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
NCT06500884Multiple Myeloma
Janssen Research & Development, LLC
Phase 2
210
Belfast, Colchester, Eastbourne, Liverpool, London, Manchester, Newcastle upon Tyne
2024-08-26
Active, closed
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991Multiple Myeloma
Janssen Research & Development, LLC
Phase 1
108
London, Manchester, Norwich, Plymouth
2024-06-07
Recruiting
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
NCT06385080Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC
Phase 1/2
287
Cambridge, Guildford, London, Manchester
2024-04-22
Recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073Crohn's Disease
Janssen Research & Development, LLC
Phase 3
120
Glasgow, London, Manchester, Oxford, Sheffield
2024-03-13
Recruiting
A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
NCT05912517Hemolytic Disease of the Fetus and Newborn
Janssen Research & Development, LLC
Phase 3
120
Birmingham, Leeds, London, Manchester, Oxford
2023-12-20
Active, closed
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
NCT05453903Leukemia, Myeloid, Acute
Janssen Research & Development, LLC
Phase 1
196
London, Manchester, Oxfordshire
2022-10-04
Active, closed
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05421663Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Janssen Research & Development, LLC
Phase 1/2
166
London, Manchester
2022-08-12
Active, closed
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
776
Cardiff, Edinburgh, London, Manchester
2021-11-17
Active, closed
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
NCT05050097Multiple Myeloma
Janssen Research & Development, LLC
Phase 1
166
London, Manchester, Oxford, Surrey
2021-09-22
Active, closed
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 4
411
Barnet, Bradford, Coventry, Leeds, Manchester, Newcastle, Stoke-on-Trent
2021-08-30
Active, closed
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
743
Birmingham, Bristol, Leeds, London, Manchester, Surrey
2021-08-19
Recruiting
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
NCT04811560Acute Leukemia
Janssen Research & Development, LLC
Phase 1/2
420
Cardiff, Leeds, Liverpool, London, Manchester, Oxfordshire, Plymouth
2021-05-19
Active, closed
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
NCT04722146Multiple Myeloma
Janssen Research & Development, LLC
Phase 1
140
London, Manchester, Surrey
2021-03-12
Active, closed
A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies
NCT04606381Neoplasms
Janssen Research & Development, LLC
Phase 1
158
Manchester, Sutton
2020-11-10
Active, closed
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
1,074
Edinburgh, London, Manchester, Nottingham, Sutton
2020-09-30
Active, closed
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
NCT04181827Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
419
Birmingham, Bristol, Cardiff, London, Manchester, Newcastle upon Tyne
2020-06-12
Active, closed
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
NCT03390504Urothelial Cancer
Janssen Research & Development, LLC
Phase 3
629
Bristol, London, Manchester, Plymouth, Sheffield, Southampton, Sutton
2018-03-23
Rows per page Showing 1–25 of 28
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 September 2026. https://priyalifescience.com/clinical-trials-uk/city/manchester

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.